A new study published in a peer-reviewed journal has found that a single dose of psilocybin-containing magic mushrooms can cause measurable anatomical changes in the brain.

This discovery provides new evidence for understanding the long-term neurological effects of psychedelics. Researchers say the findings could help develop psychedelic-based treatments for mental health conditions, but more research is needed to determine whether these structural changes have clinical significance.

American politics is undergoing a remarkable policy shift: the conservative camp, which for decades staunchly opposed hallucinogenic drugs, is now actively embracing psychedelic medicine. At the center of this transformation is a move from the traditional “war on drugs” stance toward supporting the medical use of substances like ibogaine and psilocybin.

From Opposition to Support

For decades, conservative politicians were unwavering opponents of psychedelic substances, classifying compounds like LSD and psilocybin as societal threats. However, the Trump administration’s policy marks a dramatic departure from this position.

Part of the driving force behind this shift comes from the influence of public figures like podcast host Joe Rogan, who have openly discussed ibogaine’s potential in treating addiction. Ibogaine, a naturally occurring psychedelic compound derived from the root of the West African iboga plant, has traditionally been used to treat substance dependence.

Where Science Meets Politics

Research supporting psychedelics has shown encouraging clinical trial results for psilocybin in treating depression, post-traumatic stress disorder (PTSD), and addiction. Studies from institutions like Stanford University and Johns Hopkins University have provided scientific backing for this policy shift.

However, critics argue that this policy transformation is driven more by political considerations than scientific evidence. Some medical experts warn that ibogaine carries known cardiac risks, and its safety has not been adequately validated in large-scale clinical trials.

Controversy and Concern

Organizations such as the American Psychiatric Association (APA) have expressed concern, arguing that policy decisions should be based on rigorous scientific evaluation rather than the personal experiences of public figures. The APA has previously called for a more cautious approach to the use of psychiatric medications.

This policy shift has also sparked broader discussions about drug regulatory frameworks. Supporters argue that deregulation could provide new treatment options for millions of patients with treatment-resistant depression and addiction. Opponents worry it could open Pandora’s box, potentially exacerbating substance abuse problems.

Source: The New York Times